Piracetam: adjunctive cytostatic-treatment claim — US4620973A
Peter Truog · 1986 · US4620973A · patent family 4204090
Published 1986-11-04.
Reported patent results
Reported findings
The patent reports lower chemotherapy-associated toxicity signals, without establishing independent anticancer activity.
Piracetam adjunct-to-cytostatic patent: animal toxicity experiments and an uncontrolled clinical observation in 47 patients.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Alopecia observation | No alopecia in 32/47 patients receiving adjunctive Piracetam | No matched untreated comparator or prespecified alopecia assessment established |
| Animal mortality | Lower mortality with Piracetam during a cytostatic-toxicity experiment | Absolute survivor counts not supplied in the extracted narrative · p<0.01 |
| Cardiac observation | No clinically identified cardiac damage described in a high-cumulative-exposure subgroup | Subgroup size and clear exposure units not established; no cardioprotection rate inferred |
Uncontrolled observations and incompletely specified treatment contexts cannot establish prevention of chemotherapy toxicity or tumor efficacy.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. This historical use patent proposes piracetam alongside cytostatic treatment.
This is a later indication claim, not the original discovery patent, and does not demonstrate independent anticancer activity.
- Publication
- US4620973A ↗ · 1986-11-04
- Earliest priority / filing
- 1980-02-13 / 1985-06-14
- Original applicant / assignee
- Ciba Geigy Corp
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 4204090 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Use of nootropics
Inventors: Peter Truog.
US4620973A · JPS56128713A · BE887487A · CH657527A5 · DE3104703A1 · NL8100579A · ZA81936B
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- This is a later indication claim, not the original discovery patent, and does not demonstrate independent anticancer activity.
- Uncontrolled observations and incompletely specified treatment contexts cannot establish prevention of chemotherapy toxicity or tumor efficacy.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-4204090. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Peter Truog. Piracetam: adjunctive cytostatic-treatment claim — US4620973A US4620973A · patent family 4204090 1986.
Molekul research summary: https://molekul.io/research/patent-us4620973a. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry